metastatic, non-squamous NSCLC, without EGFR mutation

Paclitaxel + Carboplatin + Bevacizumab (ECOG 4599) x 6

Maintenance Bevacizumab, until disease progression

Progression

Pemetrexed

Progression 2

Erlotinib